More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$1.71B
EPS
0.1
P/E ratio
--
Price to sales
3.83
Dividend yield
--
Beta
0.11349
Previous close
$4.41
Today's open
$4.40
Day's range
$4.20 - $4.49
52 week range
$2.94 - $6.53
show more
CEO
Lisa Graver
Employees
1460
Headquarters
Luxembourg,
Exchange
NASDAQ Global Market
Shares outstanding
390431480
Issue type
Common Stock
Healthcare
Pharmaceuticals
Alvotech (ALVO) Presents at UBS Global Biopharma Conference 2026 Transcript
Alvotech ( ALVO ) UBS Global Biopharma Conference 2026 November 17, 2026 9:00 AM EST Company Participants Robert Wessman - Founder & Executive Chairman Balaji Prasad - Chief Strategy Officer Conference Call Participants Ashwani Verma - UBS Investment Bank, Research Division Presentation Ashwani Verma UBS Investment Bank, Research Division All right. Good day, everybody.
Seeking Alpha • a day ago

What Alvotech (ALVO) Said on Its Q3 Earnings Call
Alvotech NASDAQ: ALVO expects its full-year revenue and adjusted earnings to land near the lower end of its guidance range, as the biosimilar maker works to increase deliveries following a manufacturing slowdown.
MarketBeat • Nov 12, 2026

Alvotech Announces Financial Results for the Nine Months to September 30, 2026, with a Business Update
REYKJAVIK, Iceland, Nov. 11, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB) (“Alvotech” or the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced financial results for the nine months to September 30, 2026, and provided a business update.
GlobeNewsWire • Nov 11, 2026

Alvotech (ALVO) Reports Q3 Loss, Lags Revenue Estimates
Alvotech (ALVO) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.01. This compares to a loss of $0.02 per share a year ago.
Zacks Investment Research • Nov 11, 2026

Will Alvotech (ALVO) Report Negative Earnings Next Week? What You Should Know
Alvotech (ALVO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks Investment Research • Nov 4, 2026

Alvotech: The Market Is Still Pricing The Broken Factory
Alvotech is transitioning from supply remediation to throughput, with FDA-cleared facilities and multiple key biosimilar filings advancing toward decisions this quarter. ALVO's guidance implies a significant second-half revenue and EBITDA ramp, hinging on restored manufacturing capacity and upcoming product launches. Recent manufacturing upgrades and expanded partnerships position ALVO to compete on supply reliability and cost, crucial in crowded biosimilar markets.
Seeking Alpha • Nov 3, 2026

Alvotech to Present at Upcoming Investor Conferences in November
REYKJAVIK, ICELAND (November 2, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that members of the management team will participate in upcoming investor conferences in November as follows:
GlobeNewsWire • Nov 2, 2026

Alvotech to Report Financial Results for the Nine-Month Period to September 30, 2026
REYKJAVIK, ICELAND (October 28, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB) (the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that it will release its financial results for the nine months and third quarter ended September 30, 2026 on Wednesday, November 11, 2026, after the U.S. market close.
GlobeNewsWire • Oct 28, 2026

New Strong Sell Stocks for October 21st
ALVO, CSIQ and AESI have been added to the Zacks Rank #5 (Strong Sell) List on October 21, 2026.
Zacks Investment Research • Oct 21, 2026

Alvotech receives FDA approval for new SIMLANDI® manufacturing process that more than doubles output per batch
Enhanced process increases manufacturing productivity and frees up capacity to support growing demand across Alvotech's biosimilars portfolio
GlobeNewsWire • Oct 20, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Alvotech commission-free¹. Build wealth for the long term using automated trading and transfers.